David Koelle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7782060/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nature Communications, 2022, 13, 78.	12.8	8
2	T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components. JCI Insight, 2022, 7, .	5.0	12
3	Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors. Communications Biology, 2022, 5, 133.	4.4	3
4	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Advances, 2022, 6, 1732-1740.	5.2	13
5	Response of Human Liver Tissue to Innate Immune Stimuli. Frontiers in Immunology, 2022, 13, 811551.	4.8	1
6	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens. Frontiers in Immunology, 2022, 13, 867962.	4.8	5
7	Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies. PLOS Global Public Health, 2022, 2, e0000231.	1.6	3
8	T cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibodies and disease severity. JCI Insight, 2022, 7, .	5.0	26
9	HLA-B*57:01 Complexed to a CD8 T-Cell Epitope from the HSV-2 ICP22 Protein Binds NK and T Cells through KIR3DL1. Viruses, 2022, 14, 1019.	3.3	0
10	Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants. Nature Biotechnology, 2022, 40, 1336-1340.	17.5	23
11	Donor-Derived CD4+ T Cells and Human Herpesvirus 6B Detection After Allogeneic Hematopoietic Cell Transplantation. Journal of Infectious Diseases, 2021, 223, 709-713.	4.0	4
12	Flt3-L enhances trans-epithelial migration and antigen presentation of dendritic cells adoptively transferred to genital mucosa. Journal of Controlled Release, 2021, 329, 782-793.	9.9	1
13	Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. Journal of Clinical Investigation, 2021, 131, .	8.2	72
14	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. Scientific Reports, 2021, 11, 4290.	3.3	22
15	Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2. JCI Insight, 2021, 6, .	5.0	39
16	The viral hypothesis: how herpesviruses may contribute to Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5476-5480.	7.9	20
17	Distinct populations of antigen specific tissue resident CD8 T cells in human cervix mucosa. JCl Insight, 2021, 6, .	5.0	10
18	Local Immune Control of Latent Herpes Simplex Virus Type 1 in Ganglia of Mice and Man. Frontiers in Immunology, 2021, 12, 723809.	4.8	10

#	Article	IF	CITATIONS
19	Tissue-Resident-Memory CD8+ T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. Frontiers in Immunology, 2021, 12, 735643.	4.8	15
20	Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab. Journal of Translational Autoimmunity, 2021, 4, 100114.	4.0	8
21	Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine. Blood, 2021, 138, 1556-1556.	1.4	0
22	Cross-reactive and mono-reactive SARS-CoV-2 CD4+ T cells in prepandemic and COVID-19 convalescent individuals. PLoS Pathogens, 2021, 17, e1010203.	4.7	24
23	An interferon-gamma release assay as a novel biomarker in systemic lupus erythematosus. Rheumatology, 2020, 59, 3479-3487.	1.9	5
24	SJS/TEN 2019: From science to translation. Journal of Dermatological Science, 2020, 98, 2-12.	1.9	41
25	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathogens, 2020, 16, e1008522.	4.7	11
26	Mechanisms of Endogenous HIV-1 Reactivation by Endocervical Epithelial Cells. Journal of Virology, 2020, 94, .	3.4	9
27	Polyomavirusâ€driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Molecular Carcinogenesis, 2020, 59, 807-821.	2.7	32
28	Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. Cancer Immunology Research, 2020, 8, 648-659.	3.4	28
29	The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines. Methods in Molecular Biology, 2020, 2060, 429-454.	0.9	1
30	Proteome-Wide Zika Virus CD4 T Cell Epitope and HLA Restriction Determination. ImmunoHorizons, 2020, 4, 444-453.	1.8	8
31	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research, 2019, 25, 1185-1195.	7.0	97
32	Single-cell transcriptomics reveal polyclonal memory T-cell responses in skin with positive abacavir patch test results. Journal of Allergy and Clinical Immunology, 2019, 144, 1413-1416.e7.	2.9	19
33	Conservation of molecular and cellular phenotypes of invariant NKT cells between humans and non-human primates. Immunogenetics, 2019, 71, 465-478.	2.4	8
34	A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection. Journal of Infectious Diseases, 2019, 220, 990-1000.	4.0	44
35	Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6B. Journal of Virology, 2019, 93, .	3.4	6
36	Large, Stable, Contemporary Interspecies Recombination Events in Circulating Human Herpes Simplex Viruses. Journal of Infectious Diseases, 2019, 221, 1271-1279.	4.0	21

#	Article	IF	CITATIONS
37	Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. PLoS Pathogens, 2019, 15, e1007650.	4.7	40
38	Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense. Journal of Immunology, 2019, 202, 2558-2569.	0.8	10
39	Trillions and Trillions: Herpes Simplex Virus–1 Hepatitis in an Immunocompetent Adult. Open Forum Infectious Diseases, 2019, 6, ofz465.	0.9	4
40	Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. Cancer Immunology Research, 2019, 7, 1727-1739.	3.4	23
41	Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS ONE, 2019, 14, e0226320.	2.5	20
42	Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. Journal of Virology, 2019, 93, .	3.4	11
43	Viral Genetics Modulate Orolabial Herpes Simplex Virus Type 1 Shedding in Humans. Journal of Infectious Diseases, 2019, 219, 1058-1066.	4.0	13
44	Genome-wide association study (GWAS) of human host factors influencing viral severity of herpes simplex virus type 2 (HSV-2). Genes and Immunity, 2019, 20, 112-120.	4.1	17
45	Copy Number Heterogeneity, Large Origin Tandem Repeats, and Interspecies Recombination in Human Herpesvirus 6A (HHV-6A) and HHV-6B Reference Strains. Journal of Virology, 2018, 92, .	3.4	21
46	Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus–specific type 2 immune responses. Journal of Allergy and Clinical Immunology, 2018, 141, 1144-1147.e5.	2.9	27
47	A Novel Approach of Identifying Immunodominant Self and Viral Antigen Cross-Reactive T Cells and Defining the Epitopes They Recognize. Frontiers in Immunology, 2018, 9, 2811.	4.8	3
48	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide–MHC complexes. Nature Biotechnology, 2018, 36, 1191-1196.	17.5	85
49	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications, 2018, 9, 3868.	12.8	211
50	Immunobiology of Varicella-Zoster Virus Infection. Journal of Infectious Diseases, 2018, 218, S68-S74.	4.0	95
51	Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection. Open Forum Infectious Diseases, 2018, 5, ofy184.	0.9	18
52	HHV-6B infection, T-cell reconstitution, and graft-vs-host disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1508-1517.	2.4	16
53	Multicenter study of QuantiFERON [®] -TB Gold Plus in patients with active tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 617-621.	1.2	29
54	Advances in the Characterization of the T-Cell Response to Human Herpesvirus-6. Frontiers in Immunology, 2018, 9, 1454.	4.8	12

#	Article	IF	CITATIONS
55	Ultrasensitive Capture of Human Herpes Simplex Virus Genomes Directly from Clinical Samples Reveals Extraordinarily Limited Evolution in Cell Culture. MSphere, 2018, 3, .	2.9	49
56	Comparative genomic, transcriptomic, and proteomic reannotation of human herpesvirus 6. BMC Genomics, 2018, 19, 204.	2.8	45
57	Genome-Wide Surveillance of Genital Herpes Simplex Virus Type 1 From Multiple Anatomic Sites Over Time. Journal of Infectious Diseases, 2018, 218, 595-605.	4.0	35
58	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunology Research, 2017, 5, 137-147.	3.4	73
59	Worldwide circulation of HSV-2 × HSV-1 recombinant strains. Scientific Reports, 2017, 7, 44084.	3.3	81
60	T-cell Responses to HSV-1 in Persons Who Have Survived Childhood Herpes Simplex Encephalitis. Pediatric Infectious Disease Journal, 2017, 36, 741-744.	2.0	9
61	Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. Mucosal Immunology, 2017, 10, 1259-1269.	6.0	45
62	Cytomegalovirus (CMV) Epitope–Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects. Journal of Immunology, 2017, 199, 3187-3201.	0.8	55
63	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports, 2017, 7, 8653.	3.3	41
64	Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents. Virology, 2017, 510, 90-98.	2.4	17
65	Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells. Journal of Virology, 2017, 91, .	3.4	13
66	T Cell Immunity to Varicella-Zoster Virus in the Setting of Advanced HIV and Multiple Varicella-Zoster Virus Recurrences. Viral Immunology, 2017, 30, 77-80.	1.3	9
67	Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine. Journal of Infectious Diseases, 2017, 216, 1329-1333.	4.0	4
68	Experimental Oral Herpes Simplex Virus-1 (HSV-1) Co-infection in Simian Immunodeficiency Virus (SIV)-Infected Rhesus Macaques. Frontiers in Microbiology, 2017, 8, 2342.	3.5	9
69	Elevated Spontaneous Interferon-Î ³ Secretion in Human Immunodeficiency Virus-Infected Persons. Open Forum Infectious Diseases, 2017, 4, ofx055.	0.9	9
70	Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Medicine, 2017, 14, e1002475.	8.4	22
71	In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. Journal of Infectious Diseases, 2016, 214, 23-31.	4.0	17
72	HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions. Genes and Immunity, 2016, 17, 412-418.	4.1	6

#	Article	IF	CITATIONS
73	Stability of live attenuated rotavirus vaccine with selected preservatives and primary containers. Vaccine, 2016, 34, 2483-2489.	3.8	9
74	Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. Journal of Immunology, 2016, 196, 2205-2218.	0.8	55
75	Latent Tuberculosis Infection Test Agreement in the National Health and Nutrition Examination Survey. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 493-500.	5.6	22
76	A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. Vaccine, 2016, 34, 101-109.	3.8	42
77	Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. Journal of Virology, 2015, 89, 8219-8232.	3.4	68
78	Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins. Journal of Virology, 2015, 89, 8206-8218.	3.4	37
79	Elevated Spontaneous Interferon-Gamma Secretion in HIV-Infected Persons. Journal of Allergy and Clinical Immunology, 2015, 135, AB100.	2.9	1
80	Identification of novel Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening. Tuberculosis, 2015, 95, 275-287.	1.9	19
81	Zoster Vaccination Increases the Breadth of CD4 ⁺ T Cells Responsive to Varicella Zoster Virus. Journal of Infectious Diseases, 2015, 212, 1022-1031.	4.0	45
82	A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. Journal of Virology, 2015, 89, 8497-8509.	3.4	22
83	1154Host and Pathogen Genetics Modulate HSV-1 Severity. Open Forum Infectious Diseases, 2014, 1, S342-S342.	0.9	1
84	Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Human Vaccines and Immunotherapeutics, 2014, 10, 3611-3621.	3.3	41
85	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. Cancer Immunology Research, 2014, 2, 27-36.	3.4	89
86	Development of a lowâ€dose fastâ€dissolving tablet formulation of Newcastle disease vaccine for low ost backyard poultry immunisation. Veterinary Record, 2014, 174, 504-504.	0.3	18
87	Current status and prospects for development of an HSV vaccine. Vaccine, 2014, 32, 1553-1560.	3.8	62
88	Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma. Cancer Immunology Research, 2014, 2, 1071-1079.	3.4	120
89	Virologic and Immunologic Evidence of Multifocal Genital Herpes Simplex Virus 2 Infection. Journal of Virology, 2014, 88, 4921-4931.	3.4	55
90	The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines. Methods in Molecular Biology, 2014, 1144, 305-327.	0.9	7

#	Article	IF	CITATIONS
91	T-cell immunity to human alphaherpesviruses. Current Opinion in Virology, 2013, 3, 452-460.	5.4	58
92	Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature, 2013, 497, 494-497.	27.8	257
93	Vascular E-Selectin Expression Correlates with CD8 Lymphocyte Infiltration and Improved Outcome in Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2013, 133, 2065-2073.	0.7	46
94	Local CD4 and CD8 T-Cell Reactivity to HSV-1 Antigens Documents Broad Viral Protein Expression and Immune Competence in Latently Infected Human Trigeminal Ganglia. PLoS Pathogens, 2013, 9, e1003547.	4.7	89
95	CD4 T-Cell Memory Responses to Viral Infections of Humans Show Pronounced Immunodominance Independent of Duration or Viral Persistence. Journal of Virology, 2013, 87, 2617-2627.	3.4	29
96	Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers. Clinical Cancer Research, 2013, 19, 5351-5360.	7.0	176
97	A Novel DNA Vaccine Technology Conveying Protection against a Lethal Herpes Simplex Viral Challenge in Mice. PLoS ONE, 2013, 8, e76407.	2.5	47
98	Abstract IA17: Merkel cell carcinoma therapy with viral oncoprotein-specific T cells in combination with immunostimulatory adjuvants , 2013, , .		0
99	Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. Journal of General Virology, 2012, 93, 1305-1315.	2.9	35
100	Peripheral Blood CD4 T-Cell and Plasmacytoid Dendritic Cell (pDC) Reactivity to Herpes Simplex Virus 2 and pDC Number Do Not Correlate with the Clinical or Virologic Severity of Recurrent Genital Herpes. Journal of Virology, 2012, 86, 9952-9963.	3.4	23
101	Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet, The, 2012, 379, 641-647.	13.7	104
102	An Effector Phenotype of CD8 ⁺ T Cells at the Junction Epithelium during Clinical Quiescence of Herpes Simplex Virus 2 Infection. Journal of Virology, 2012, 86, 10587-10596.	3.4	55
103	Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation, 2012, 122, 654-673.	8.2	83
104	Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. Journal of Clinical Investigation, 2012, 122, 3024-3024.	8.2	1
105	Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival. Journal of Clinical Oncology, 2011, 29, 1539-1546.	1.6	272
106	Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nature Medicine, 2011, 17, 989-995.	30.7	193
107	Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine, 2011, 29, 8520-8529.	3.8	70
108	Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors. PLoS ONE, 2011, 6, e16819.	2.5	42

#	Article	IF	CITATIONS
109	Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood. Clinical Cancer Research, 2011, 17, 6671-6680.	7.0	128
110	Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clinical and Experimental Immunology, 2011, 167, 47-58.	2.6	33
111	HSV-2: in pursuit of a vaccine. Journal of Clinical Investigation, 2011, 121, 4600-4609.	8.2	118
112	Immunobiology of Herpes Simplex Virus and Cytomegalovirus Infections of the Fetus and Newborn. Current Immunology Reviews, 2010, 6, 38-55.	1.2	37
113	Reduction of herpes simplex virus type-2 replication in cell cultures and in rodent models with peptide-conjugated morpholino oligomers. Antiviral Therapy, 2010, 15, 1141-1149.	1.0	14
114	Diversity in CD8+ T Cell Function and Epitope Breadth Among Persons with Genital Herpes. Journal of Clinical Immunology, 2010, 30, 703-722.	3.8	54
115	Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. Journal of Controlled Release, 2010, 148, 327-333.	9.9	89
116	Public TCR Use by Herpes Simplex Virus-2–Specific Human CD8 CTLs. Journal of Immunology, 2010, 184, 3063-3071.	0.8	38
117	Use of Acyclovir for Suppression of Human Immunodeficiency Virus Infection Is Not Associated with Genotypic Evidence of Herpes Simplex Virus Type 2 Resistance to Acyclovir: Analysis of Specimens from Three Phase III Trials. Journal of Clinical Microbiology, 2010, 48, 3496-3503.	3.9	17
118	Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18973-18978.	7.1	112
119	APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sexually Transmitted Infections, 2010, 86, 202-206.	1.9	40
120	Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiology, 2010, 5, 221-239.	2.0	68
121	DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine, 2010, 28, 7483-7491.	3.8	59
122	Evasion of the Mucosal Innate Immune System by Herpes Simplex Virus Type 2. Journal of Virology, 2009, 83, 12559-12568.	3.4	54
123	Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. Journal of General Virology, 2009, 90, 1153-1163.	2.9	33
124	ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. Journal of Immunological Methods, 2009, 347, 36-45.	1.4	27
125	Persistence of HIV-1 receptor–positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nature Medicine, 2009, 15, 886-892.	30.7	341
126	Definition of epitopes and antigens recognized by vaccinia specific immune responses: Their conservation in variola virus sequences, and use as a model system to study complex pathogens. Vaccine, 2009, 27, G21-G26.	3.8	43

#	Article	IF	CITATIONS
127	Recombinant Listeria monocytogenes expressing an immunodominant peptide fails to protect after intravaginal challenge with herpes simplex virus-2. Archives of Virology, 2008, 153, 1165-1169.	2.1	5
128	Herpes Simplex: Insights on Pathogenesis and Possible Vaccines. Annual Review of Medicine, 2008, 59, 381-395.	12.2	187
129	Phase I Dose-Escalation Study of a Monovalent Heat Shock Protein 70-Herpes Simplex Virus Type 2 (HSV-2) Peptide-Based Vaccine Designed To Prime or Boost CD8 T-Cell Responses in HSV-Nail`ve and HSV-2-Infected Subjects. Vaccine Journal, 2008, 15, 773-782.	3.1	23
130	Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine Administered to Healthy, HSV-2-Seronegative Adults by a Needle-Free Injection System. Vaccine Journal, 2008, 15, 1638-1643.	3.1	65
131	One-Day Regimen of Valacyclovir for Treatment of Recurrent Genital Herpes Simplex Virus 2 Infection. Sexually Transmitted Diseases, 2008, 35, 383-386.	1.7	14
132	An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling. Journal of Virology, 2008, 82, 7120-7134.	3.4	55
133	Doctor, Why Is My Herpes So Bad? The Search Continues. Journal of Infectious Diseases, 2008, 197, 331-334.	4.0	4
134	HSV-1 and 2: immunobiology and host response. , 2007, , 616-641.		2
135	Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus. Journal of Immunology, 2007, 178, 6374-6386.	0.8	38
136	Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. Journal of Experimental Medicine, 2007, 204, 595-603.	8.5	315
137	Polymorphisms in <i>TLR2</i> Are Associated with Increased Viral Shedding and Lesional Rate in Patients with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2007, 196, 505-509.	4.0	100
138	Repeatâ€Region Polymorphisms in the Gene for the Dendritic Cell–Specific Intercellular Adhesion Moleculeâ€3–Grabbing Nonintegrin–Related Molecule: Effects on HIVâ€1 Susceptibility. Journal of Infectious Diseases, 2006, 193, 698-702.	4.0	47
139	Fulminant, Acyclovir-Resistant, Herpes Simplex Virus Type 2 Hepatitis in an Immunocompetent Woman. Journal of Clinical Microbiology, 2006, 44, 1584-1586.	3.9	50
140	Innate Immune Responses to Herpes Simplex Virus Type 2 Influence Skin Homing Molecule Expression by Memory CD4 + Lymphocytes. Journal of Virology, 2006, 80, 2863-2872.	3.4	17
141	Diversity of the CD8 + T-Cell Response to Herpes Simplex Virus Type 2 Proteins among Persons with Genital Herpes. Journal of Virology, 2006, 80, 5509-5515.	3.4	95
142	Human CD4 + CD25 high Cells Suppress Proliferative Memory Lymphocyte Responses to Herpes Simplex Virus Type 2. Journal of Virology, 2006, 80, 8271-8273.	3.4	31
143	Vaccines for herpes simplex virus infections. Current Opinion in Investigational Drugs, 2006, 7, 136-41.	2.3	29
144	Homing in on the Cellular Immune Response to HSV-2 in Humans*. American Journal of Reproductive Immunology, 2005, 53, 172-181.	1.2	19

#	Article	IF	CITATIONS
145	A Case of Ramsay Hunt-Like Syndrome Caused by Herpes Simplex Virus Type 2. Clinical Infectious Diseases, 2005, 40, 1545-1547.	5.8	13
146	Longitudinal Analysis of Herpes Simplex Virus–Specific CD4+Cell Clonotypes in Infected Tissues and Blood. Journal of Infectious Diseases, 2005, 191, 2012-2021.	4.0	14
147	Diversity in the Acute CD8 T Cell Response to Vaccinia Virus in Humans. Journal of Immunology, 2005, 175, 7550-7559.	0.8	72
148	Herpes Simplex Virus Infection of Human Dendritic Cells Induces Apoptosis and Allows Cross-Presentation via Uninfected Dendritic Cells. Journal of Immunology, 2005, 174, 2220-2227.	0.8	152
149	Expression of Cutaneous Lymphocyte–Associated Antigen and Eâ€selectin Ligand by Circulating Human Memory CD4+T Lymphocytes Specific for Herpes Simplex Virus Type 2. Journal of Infectious Diseases, 2005, 191, 243-254.	4.0	33
150	Prospects for Developing an Effective Vaccine Against Ocular Herpes Simplex Virus Infection. Current Eye Research, 2005, 30, 929-942.	1.5	47
151	Persistence of Herpes Simplex Virus Type 2 VP16-Specific CD4+ T Cells. Human Immunology, 2005, 66, 777-787.	2.4	3
152	Prevalence of Human Herpesvirus-8 Salivary Shedding in HIV Increases with CD4 Count. Journal of Dental Research, 2004, 83, 639-643.	5.2	17
153	Reduced Levels of Neutralizing Antibodies to Kaposi Sarcoma–Associated Herpesvirus in Persons with a History of Kaposi Sarcoma. Journal of Infectious Diseases, 2004, 189, 2016-2022.	4.0	40
154	Autoreactive T Cells in Healthy Individuals. Journal of Immunology, 2004, 172, 5967-5972.	0.8	309
155	Expression cloning for the discovery of viral antigens and epitopes recognized by T cells. Methods, 2003, 29, 213-226.	3.8	41
156	A Naturally Selected Dimorphism within the HLA-B44 Supertype Alters Class I Structure, Peptide Repertoire, and T Cell Recognition. Journal of Experimental Medicine, 2003, 198, 679-691.	8.5	192
157	Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12899-12904.	7.1	55
158	Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research. Clinical Microbiology Reviews, 2003, 16, 96-113.	13.6	239
159	T Cell Immunity to Herpes Simplex Viruses in Seronegative Subjects: Silent Infection or Acquired Immunity?. Journal of Immunology, 2003, 170, 4380-4388.	0.8	57
160	Cellular Immunity in Monozygotic Twins Discordant for Chronic Fatigue Syndrome. Journal of Infectious Diseases, 2002, 185, 828-832.	4.0	30
161	:Clinical Virology, 2nd Edition. Clinical Infectious Diseases, 2002, 35, 1578-1578.	5.8	0
162	Markers of Viral Infection in Monozygotic Twins Discordant for Chronic Fatigue Syndrome. Clinical Infectious Diseases, 2002, 35, 518-525.	5.8	66

#	Article	IF	CITATIONS
163	High Incidence of Ganciclovirâ€Resistant Cytomegalovirus Infection among Lung Transplant Recipients Receiving Preemptive Therapy. Journal of Infectious Diseases, 2002, 185, 20-27.	4.0	216
164	Herpes simplex virus type 2–specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles. Blood, 2002, 99, 3844-3847.	1.4	60
165	HHV-8 infection: a model for reactivation and transmission. Reviews in Medical Virology, 2002, 12, 47-63.	8.3	40
166	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	103
167	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	72
168	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. Journal of Clinical Investigation, 2002, 110, 537-548.	8.2	30
169	Rapid epitope identification from complex class-II-restricted T-cell antigens. Trends in Immunology, 2001, 22, 583-588.	6.8	52
170	Human Herpesvirus 8 Infection and Kaposi's Sarcoma among Human Immunodeficiency Virus–Infected and –Uninfected Women. Journal of Infectious Diseases, 2001, 183, 1130-1134.	4.0	55
171	Herpes Simplex Virus Shedding and Plasma Human Immunodeficiency Virus RNA Levels in Coinfected Women. Clinical Infectious Diseases, 2001, 33, 885-890.	5.8	21
172	CD8 CTL from Genital Herpes Simplex Lesions: Recognition of Viral Tegument and Immediate Early Proteins and Lysis of Infected Cutaneous Cells. Journal of Immunology, 2001, 166, 4049-4058.	0.8	117
173	Tetramer-Guided Epitope Mapping: Rapid Identification and Characterization of Immunodominant CD4+ T Cell Epitopes from Complex Antigens. Journal of Immunology, 2001, 166, 6665-6670.	0.8	135
174	Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. Journal of Clinical Investigation, 2001, 107, 505-517.	8.2	109
175	Mucosal Shedding of Human Herpesvirus 8 in Men. New England Journal of Medicine, 2000, 343, 1369-1377.	27.0	440
176	Herpes simplex virus: the importance of asymptomatic shedding. Journal of Antimicrobial Chemotherapy, 2000, 45, 1-8.	3.0	129
177	HLA-DQ Tetramers Identify Epitope-Specific T Cells in Peripheral Blood of Herpes Simplex Virus Type 2-Infected Individuals: Direct Detection of Immunodominant Antigen-Responsive Cells. Journal of Immunology, 2000, 164, 4244-4249.	0.8	118
178	Long Term Persistence of Herpes Simplex Virus-Specific CD8+ CTL in Persons with Frequently Recurring Genital Herpes. Journal of Immunology, 2000, 165, 1146-1152.	0.8	52
179	CD4 T-Cell Responses to Herpes Simplex Virus Type 2 Major Capsid Protein VP5: Comparison with Responses to Tegument and Envelope Glycoproteins. Journal of Virology, 2000, 74, 11422-11425.	3.4	39
180	Antigenâ€Specific T Cells Localize to the Uterine Cervix in Women with Genital Herpes Simplex Virus Type 2 Infection. Journal of Infectious Diseases, 2000, 182, 662-670.	4.0	47

#	Article	IF	CITATIONS
181	Tegument-Specific, Virus-Reactive CD4 T Cells Localize to the Cornea in Herpes Simplex Virus Interstitial Keratitis in Humans. Journal of Virology, 2000, 74, 10930-10938.	3.4	83
182	Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet, The, 2000, 356, 645-649.	13.7	505
183	MHC-peptide ligand interactions establish a functional threshold for antigen-specific T cell recognition. Human Immunology, 1999, 60, 608-618.	2.4	13
184	Peptide binding affinity and pH variation establish functional thresholds for activation of HLA-DQ-restricted T cell recognition. Human Immunology, 1999, 60, 619-626.	2.4	3
185	An Important Role for Major Histocompatibility Complex Class I-Restricted T Cells, and a Limited Role for Gamma Interferon, in Protection of Mice against Lethal Herpes Simplex Virus Infection. Journal of Virology, 1999, 73, 2058-2063.	3.4	36
186	Reactivities of Human Sera with Human Herpesvirus-8-Infected BCBL-1 Cells and Identification of HHV-8-Specific Proteins and Glycoproteins and the Encoding cDNAs. Virology, 1998, 243, 208-217.	2.4	76
187	Tipping the scales of herpes simplex virus reactivation: The important responses are local. Nature Medicine, 1998, 4, 381-382.	30.7	89
188	Famciclovir for the Suppression of Symptomatic and Asymptomatic Herpes Simplex Virus Reactivation in HIV-Infected Persons: A Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine, 1998, 128, 21.	3.9	156
189	Chronic Vulvar Ulceration in an Immunocompetent Woman Due to Acyclovirâ€Resistant, Thymidine Kinaseâ€Deficient Herpes Simplex Virus. Journal of Infectious Diseases, 1998, 177, 543-550.	4.0	67
190	Herpes Simplex Virus Type 1 Renders Infected Cells Resistant to Cytotoxic T-Lymphocyte-Induced Apoptosis. Journal of Virology, 1998, 72, 436-441.	3.4	101
191	Human Herpesvirus 8 in the Prostate Glands of Men with Kaposi's Sarcoma. Journal of Virology, 1998, 72, 6223-6227.	3.4	64
192	Recognition of Herpes Simplex Virus Type 2 Tegument Proteins by CD4 T Cells Infiltrating Human Genital Herpes Lesions. Journal of Virology, 1998, 72, 7476-7483.	3.4	81
193	Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes Journal of Clinical Investigation, 1998, 101, 1500-1508.	8.2	240
194	Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. Journal of Immunology, 1998, 161, 3527-35.	0.8	59
195	Frequent Detection of Kaposi's Sarcoma—Associated Herpesvirus (Human Herpesvirus 8) DNA in Saliva of Human Immunodeficiency Virusâ€Infected Men: Clinical and Immunologic Correlates. Journal of Infectious Diseases, 1997, 176, 94-102.	4.0	224
196	Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 10289-10294.	7.1	133
197	Preferential presentation of herpes simplex virus T-cell antigen by HLA DQA1*0501/DQB1*0201 in comparison to HLA DQA1*0201/DQB1*0201. Human Immunology, 1997, 53, 195-205.	2.4	21
198	Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma. Journal of Virology, 1997, 71, 7083-7087.	3.4	174

#	Article	IF	CITATIONS
199	Interactions of peptide side chains with structurally complementary pockets in DQ molecules are critical for allele-specific peptide binding and T cell reactivity. Human Immunology, 1996, 47, 17.	2.4	1
200	Allelic variants of MHC class II Molecules can ACT as partial agonists of antigen-specific T cell responses. Human Immunology, 1996, 47, 149.	2.4	3
201	Primary and Secondary Syphilis Lesions Contain mRNA for Thl Cytokines. Journal of Infectious Diseases, 1996, 173, 491-495.	4.0	121
202	HLA-DQB1 codon 57 is critical for peptide binding and recognition Journal of Experimental Medicine, 1996, 183, 1253-1258.	8.5	110
203	High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. Journal of Virology, 1996, 70, 8165-8168.	3.4	83
204	Direct Recovery of Herpes Simplex Virus (HSV)-Specific T Lymphocyte Clones from Recurrent Genital HSV-2 Lesions. Journal of Infectious Diseases, 1994, 169, 956-961.	4.0	142
205	Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. Journal of Virology, 1994, 68, 2803-2810.	3.4	128
206	Herpes simplex virus infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T lymphocytes Journal of Clinical Investigation, 1993, 91, 961-968.	8.2	80
207	Asymptomatic Reactivation of Herpes Simplex Virus in Women after the First Episode of Genital Herpes. Annals of Internal Medicine, 1992, 116, 433-437.	3.9	183